US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Onconetix Inc.

0.0543

-0.0052-8.74%

Volume:2.72M

Turnover:146.84K

Market Cap:789.80K

PE:0.00

High:0.0580

Open:0.0550

Low:0.0520

Close:0.0595

Loading ...

Overview Company News Filings

BRIEF-Onconetix Sets Stage For Potential Business Combination With Ocuvex Therapeutics

Onconetix, Ocuvex Therapeutics Sign Letter of Intent for Potential Merger; Shares Up Pre-Bell

MT Newswires Live

Onconetix Signs Letter of Intent for Potential Business Combination With Ocuvex Therapeutics, Inc.

THOMSON REUTERS

Onconetix Inc - Onconetix and Ocuvex Will Continue Negotiations to Enter Into a Definitive Agreement

THOMSON REUTERS

Onconetix- Post Close, Pre-Closing Ocuvex Equity Holders Will Own About 90% of Equity Interests in Onconetix

THOMSON REUTERS

Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.

Onconetix Names Interim CFO Karina Fedasz as Interim CEO

Onconetix claims validation of prostate cancer test Proclarix in Danish cohort

Onconetix Announces Successful Clinical Validation of Its Innovative Prostate Cancer Test Proclarix in a Danish Cohort

THOMSON REUTERS

BRIEF-Onconetix Says Ralph Schiess Resigns As Interim CEO And Chief Science Officer

Onconetix Inc: Approved an Increase to Board's Size From Five to Six Members

THOMSON REUTERS

Onconetix Inc - Appoints James Sapirstein as Executive Chairman

THOMSON REUTERS

Onconetix Inc - on Feb 24 Ralph Schiess Resigns as Interim CEO and Chief Science Officer

THOMSON REUTERS

Onconetix Files for Offer, Sale From Time to Time by Keystone Capital Partners Llc of up to 50 Mln Shares of Common Stock -SEC Filing

THOMSON REUTERS

BRIEF-Onconetix Inc files for resale of up to 10.6 mln shares

BRIEF-Onconetix Inc offering up to 6,250,000 shares of common stock

Onconetix Inc - Offering up to 6,250,000 Shares of Common Stock

THOMSON REUTERS

Onconetix Inc Files for Resale of up to 10.6 Mln Shares by the Selling Stockholders - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ONCO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONCO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONCO\",,,,,undefined,":{"symbol":"ONCO","market":"US","secType":"STK","nameCN":"Onconetix Inc.","latestPrice":0.0543,"timestamp":1745265600000,"preClose":0.0595,"halted":0,"volume":2717063,"delay":0,"floatShares":8294734,"shares":14545203,"eps":-71.23981,"marketStatus":"Pre-Mkt","change":-0.0052,"latestTime":"04-22 04:23:09 EDT","open":0.055,"high":0.058,"low":0.052,"amount":146840.346866951,"amplitude":0.10084,"askPrice":0.063,"askSize":100,"bidPrice":0.05,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-71.23981,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745328600000},"marketStatusCode":1,"adr":0,"listingDate":1645160400000,"exchange":"NASDAQ","adjPreClose":0.0543,"postHourTrading":{"tag":"盘后","latestPrice":0.0521,"preClose":0.0543,"latestTime":"19:53 EDT","volume":87416,"amount":4666.32255,"timestamp":1745279582315},"volumeRatio":0.9840872757272007},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONCO\",,,,,undefined,":{"symbol":"ONCO","floatShares":8294734,"roa":"-19.14%","roe":"-201.34%","lyrEps":-87.44996,"volumeRatio":0.9840872757272007,"shares":14545203,"dividePrice":0,"high":0.058,"amplitude":0.10084,"preClose":0.0595,"low":0.052,"week52Low":0.0502,"pbRate":"0.02","psRate":"0.42","week52High":21.4,"institutionHeld":0,"latestPrice":0.0543,"committee":0.333333,"eps":-71.23981,"divideRate":0,"volume":2717063,"delay":0,"ttmEps":-71.23981,"open":0.055,"prevYearClose":0.63,"prevWeekClose":0.0595,"prevMonthClose":0.078,"prevQuarterClose":0.078,"fiveDayClose":0.0623,"twentyDayClose":0.128,"sixtyDayClose":0.48},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONCO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525890631","title":"BRIEF-Onconetix Sets Stage For Potential Business Combination With Ocuvex Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2525890631","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525890631?lang=en_us&edition=fundamental","pubTime":"2025-04-08 21:25","pubTimestamp":1744118718,"startTime":"0","endTime":"0","summary":"BRIEF-Onconetix Sets Stage For Potential Business Combination With Ocuvex TherapeuticsApril 8 (Reuters) - Onconetix and Ocuvex Therapeutics:ONCONETIX SIGNS LETTER OF INTENT FOR POTENTIAL BUSINESS COMB","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM0U0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCO"],"gpt_icon":0},{"id":"2525977538","title":"Onconetix, Ocuvex Therapeutics Sign Letter of Intent for Potential Merger; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2525977538","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525977538?lang=en_us&edition=fundamental","pubTime":"2025-04-08 21:14","pubTimestamp":1744118096,"startTime":"0","endTime":"0","summary":"Onconetix  and Ocuvex Therapeutics said Tuesday they have signed a non-binding letter of intent for a potential merger.The companies said that as part of the potential deal, Onconetix is expected to acquire Ocuvex in exchange for newly issued Onconetix shares, with Ocuvex stockholders holding about a 90% stake in Onconetix.No specific financial terms were provided. The companies said they will continue talks for a definite agreement but said there are no guarantees that a definite deal will be reached.Shares of Onconetix were 82% higher in recent Tuesday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4007","ONCO","LENZ"],"gpt_icon":0},{"id":"2525891279","title":"Onconetix Signs Letter of Intent for Potential Business Combination With Ocuvex Therapeutics, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2525891279","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525891279?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:30","pubTimestamp":1744115456,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM173:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCO"],"gpt_icon":0},{"id":"2525891750","title":"Onconetix Inc - Onconetix and Ocuvex Will Continue Negotiations to Enter Into a Definitive Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2525891750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525891750?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:30","pubTimestamp":1744115416,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM0U0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCO"],"gpt_icon":0},{"id":"2525389120","title":"Onconetix- Post Close, Pre-Closing Ocuvex Equity Holders Will Own About 90% of Equity Interests in Onconetix","url":"https://stock-news.laohu8.com/highlight/detail?id=2525389120","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525389120?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:30","pubTimestamp":1744115416,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM0U0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2525194894","title":"Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2525194894","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525194894?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:30","pubTimestamp":1744115400,"startTime":"0","endTime":"0","summary":"CINCINNATI, April 08, 2025  -- Onconetix, Inc.    and Ocuvex Therapeutics, Inc. , a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options, today announced that they have signed a Non-Binding Letter of Intent contemplating a potential business combination transaction with Ocuvex.Andrew J. Oakley, Chairman of the Board of Onconetix, stated, “We are excited about the opportunity to combine forces with Ocuvex, whose pipeline of commercial and late clinical stage ophthalmic assets will immediately expand our reach beyond oncology , enhancing shareholder value.”","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onconetix-signs-letter-intent-potential-123000397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4007","BK4139","ONCO"],"gpt_icon":0},{"id":"2524217649","title":"Onconetix Names Interim CFO Karina Fedasz as Interim CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2524217649","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524217649?lang=en_us&edition=fundamental","pubTime":"2025-04-04 06:34","pubTimestamp":1743719640,"startTime":"0","endTime":"0","summary":"Onconetix on Thursday said it named its interim Chief Financial Officer, Karina Fedasz, as interim Chief Executive Officer, effective immediately.Also on Thursday, the biotechnology company said James Sapirstein resigned as executive chairman and as a member of the board.Fedasz has helped companies raise capital, model and forecast business, manage cash flow and conduct mergers and acquisitions for more than two decades, Onconetix said. She has been interim CFO of Onconetix since June 2024. Before that, she worked with various clients, including a not-for-profit and an early-stage artificial intelligence and data-driven health and wellness tracker.Prior to that, Fedasz was head of business development for Evofem Biosciences, and also served in various positions of increasing responsibility, including CFO, at IDW Media Holdings, Onconetix said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCO"],"gpt_icon":0},{"id":"2522079374","title":"Onconetix claims validation of prostate cancer test Proclarix in Danish cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2522079374","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522079374?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:50","pubTimestamp":1742907044,"startTime":"0","endTime":"0","summary":"Discover stocks' market position with detailed  competitor analyses.Read More on ONCO:Questions or Comments about the article?Biotech Alert: Searches spiking for these stocks today. Onconetix to Present Proclarix at EAU Congress 2025. Onconetix announces new clinical data for Proclarix to be presented at EAU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/onconetix-claims-validation-prostate-cancer-125044227.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onconetix-claims-validation-prostate-cancer-125044227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4022","ONCO","R","BK4232","BK4139"],"gpt_icon":0},{"id":"2521723270","title":"Onconetix Announces Successful Clinical Validation of Its Innovative Prostate Cancer Test Proclarix in a Danish Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2521723270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521723270?lang=en_us&edition=fundamental","pubTime":"2025-03-24 20:45","pubTimestamp":1742820300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA6DNY0C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCO"],"gpt_icon":0},{"id":"2516300915","title":"BRIEF-Onconetix Says Ralph Schiess Resigns As Interim CEO And Chief Science Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2516300915","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516300915?lang=en_us&edition=fundamental","pubTime":"2025-03-01 06:35","pubTimestamp":1740782158,"startTime":"0","endTime":"0","summary":"BRIEF-Onconetix Says Ralph Schiess Resigns As Interim CEO And Chief Science OfficerFeb 28  - Onconetix Inc ONCO.O:ONCONETIX INC - ON FEB 24 RALPH SCHIESS RESIGNS AS INTERIM CEO AND CHIEF SCIENCE OFFICERONCONETIX INC - APPOINTS JAMES SAPIRSTEIN AS EXECUTIVE CHAIRMANONCONETIX INC: APPROVED AN INCREASE TO BOARD'S SIZE FROM FIVE TO SIX MEMBERSSource text: [ID:n0001213900-25-018867]Further company coverage: ONCO.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ1U5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2516686300","title":"Onconetix Inc: Approved an Increase to Board's Size From Five to Six Members","url":"https://stock-news.laohu8.com/highlight/detail?id=2516686300","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516686300?lang=en_us&edition=fundamental","pubTime":"2025-03-01 06:31","pubTimestamp":1740781887,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ1U5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2516005233","title":"Onconetix Inc - Appoints James Sapirstein as Executive Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2516005233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516005233?lang=en_us&edition=fundamental","pubTime":"2025-03-01 06:31","pubTimestamp":1740781887,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ1U5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCO"],"gpt_icon":0},{"id":"2516005103","title":"Onconetix Inc - on Feb 24 Ralph Schiess Resigns as Interim CEO and Chief Science Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2516005103","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516005103?lang=en_us&edition=fundamental","pubTime":"2025-03-01 06:31","pubTimestamp":1740781887,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ1U5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2506378600","title":"Onconetix Files for Offer, Sale From Time to Time by Keystone Capital Partners Llc of up to 50 Mln Shares of Common Stock -SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2506378600","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506378600?lang=en_us&edition=fundamental","pubTime":"2025-01-27 19:18","pubTimestamp":1737976680,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nFWN3OL086:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCO"],"gpt_icon":0},{"id":"2480869378","title":"BRIEF-Onconetix Inc files for resale of up to 10.6 mln shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2480869378","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480869378?lang=en_us&edition=fundamental","pubTime":"2024-11-02 06:14","pubTimestamp":1730499298,"startTime":"0","endTime":"0","summary":"Nov 1 (Reuters) - Onconetix Inc   :   * ONCONETIX INC FILES FOR RESALE OF UP TO 10.6 MILLION SHARES BY THE SELLING STOCKHOLDERS - SEC FILINGSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCO","BK4139","BK4008","UP"],"gpt_icon":0},{"id":"2480869320","title":"BRIEF-Onconetix Inc offering up to 6,250,000 shares of common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2480869320","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480869320?lang=en_us&edition=fundamental","pubTime":"2024-11-02 06:14","pubTimestamp":1730499262,"startTime":"0","endTime":"0","summary":"Nov 1 (Reuters) - Onconetix Inc   :   * ONCONETIX INC - OFFERING UP TO 6,250,000 SHARES OF COMMON STOCKSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4008","UP","ONCO"],"gpt_icon":0},{"id":"2480868922","title":"Onconetix Inc - Offering up to 6,250,000 Shares of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2480868922","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480868922?lang=en_us&edition=fundamental","pubTime":"2024-11-02 05:08","pubTimestamp":1730495299,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241101:nFWN3M81P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCO"],"gpt_icon":0},{"id":"2480086899","title":"Onconetix Inc Files for Resale of up to 10.6 Mln Shares by the Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2480086899","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480086899?lang=en_us&edition=fundamental","pubTime":"2024-11-02 05:07","pubTimestamp":1730495273,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241101:nFWN3M81MH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCO"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONCO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-09-24","symbol":"ONCO","defaultRemindTime":1727184600000,"type":"split","dateTimestamp":1727150400000,"forFactor":40,"toFactor":1,"ratio":40},{"market":"US","date":"2024-05-20","symbol":"ONCO","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1716177600000,"reportTimeType":"post","actualEps":-0.16},{"date":"2024-04-11","symbol":"ONCO","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1712865600000,"name":null,"time":"Post Market","dateTimestamp":1712808000000,"actualEps":null},{"market":"US","date":"2023-11-17","symbol":"ONCO","fiscalQuarterEnding":"2023/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1700197200000,"reportTimeType":"post","actualEps":-0.28},{"market":"US","date":"2023-10-20","symbol":"ONCO","fiscalQuarterEnding":"2023/06","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1697774400000,"reportTimeType":"post","actualEps":-0.43}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONCO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONCO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONCO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONCO","date":"2025-04-17","current":-0.00958,"percent":0.996753,"low":-0.968106,"twenty":-0.202765,"median":-0.095559,"eighty":-0.067511,"high":-0.009323,"avg":-0.16606,"sd":0.193179,"marketCap":494366},"quantilePoints":[{"date":"2023-12-29","current":-0.201955,"twenty":-0.205826,"median":-0.201955,"eighty":-0.193917,"marketCap":3691085},{"date":"2024-01-05","current":-0.194459,"twenty":-0.201955,"median":-0.195264,"eighty":-0.193719,"marketCap":3554077},{"date":"2024-01-12","current":-0.190736,"twenty":-0.197125,"median":-0.193719,"eighty":-0.190736,"marketCap":3486030},{"date":"2024-01-19","current":-0.173836,"twenty":-0.19628,"median":-0.192899,"eighty":-0.180094,"marketCap":3177158},{"date":"2024-01-26","current":-0.342039,"twenty":-0.19628,"median":-0.189647,"eighty":-0.1728,"marketCap":6251352},{"date":"2024-02-02","current":-0.174037,"twenty":-0.202407,"median":-0.192246,"eighty":-0.173635,"marketCap":3180835},{"date":"2024-02-09","current":-0.164782,"twenty":-0.198091,"median":-0.186679,"eighty":-0.170436,"marketCap":3011681},{"date":"2024-02-16","current":-0.205696,"twenty":-0.198091,"median":-0.184801,"eighty":-0.168042,"marketCap":3759458},{"date":"2024-02-23","current":-0.206429,"twenty":-0.205989,"median":-0.188558,"eighty":-0.169852,"marketCap":3772853},{"date":"2024-03-01","current":-0.208872,"twenty":-0.20842,"median":-0.192572,"eighty":-0.172015,"marketCap":3817502},{"date":"2024-03-08","current":-0.22182,"twenty":-0.213025,"median":-0.193719,"eighty":-0.17277,"marketCap":4054143},{"date":"2024-03-15","current":-0.201665,"twenty":-0.217422,"median":-0.196597,"eighty":-0.172951,"marketCap":3685787},{"date":"2024-03-22","current":-0.203986,"twenty":-0.21515,"median":-0.197125,"eighty":-0.173514,"marketCap":3728204},{"date":"2024-03-28","current":-0.2002,"twenty":-0.212952,"median":-0.198734,"eighty":-0.173916,"marketCap":3658998},{"date":"2024-04-05","current":-0.204475,"twenty":-0.211193,"median":-0.198734,"eighty":-0.174238,"marketCap":3737134},{"date":"2024-04-12","current":-0.093154,"twenty":-0.209947,"median":-0.197125,"eighty":-0.174238,"marketCap":3484866},{"date":"2024-04-19","current":-0.079022,"twenty":-0.209385,"median":-0.195935,"eighty":-0.172739,"marketCap":2956187},{"date":"2024-04-26","current":-0.07186,"twenty":-0.2087,"median":-0.194214,"eighty":-0.166713,"marketCap":2688255},{"date":"2024-05-03","current":-0.067443,"twenty":-0.208428,"median":-0.193586,"eighty":-0.15949,"marketCap":2523030},{"date":"2024-05-10","current":-0.066787,"twenty":-0.208202,"median":-0.192246,"eighty":-0.083892,"marketCap":2498469},{"date":"2024-05-17","current":-0.084155,"twenty":-0.207504,"median":-0.190061,"eighty":-0.075083,"marketCap":3148205},{"date":"2024-05-24","current":-0.069112,"twenty":-0.206722,"median":-0.188558,"eighty":-0.074211,"marketCap":3157136},{"date":"2024-05-31","current":-0.116278,"twenty":-0.206282,"median":-0.18621,"eighty":-0.07464,"marketCap":5311760},{"date":"2024-06-07","current":-0.08705,"twenty":-0.205452,"median":-0.178162,"eighty":-0.074985,"marketCap":3976563},{"date":"2024-06-14","current":-0.070578,"twenty":-0.204475,"median":-0.174289,"eighty":-0.074605,"marketCap":3224120},{"date":"2024-06-21","current":-0.075759,"twenty":-0.204269,"median":-0.173433,"eighty":-0.074474,"marketCap":3460793},{"date":"2024-06-28","current":-0.100148,"twenty":-0.204171,"median":-0.17293,"eighty":-0.07408,"marketCap":4574945},{"date":"2024-07-05","current":-0.078056,"twenty":-0.203986,"median":-0.171849,"eighty":-0.074605,"marketCap":3565733},{"date":"2024-07-12","current":-0.070578,"twenty":-0.203986,"median":-0.1678,"eighty":-0.07371,"marketCap":3224120},{"date":"2024-07-15","current":-0.074977,"twenty":-0.203742,"median":-0.166895,"eighty":-0.073758,"marketCap":3425069},{"date":"2024-08-02","current":-0.097024,"twenty":-0.203498,"median":-0.165989,"eighty":-0.073806,"marketCap":4432207},{"date":"2024-08-09","current":-0.087113,"twenty":-0.202765,"median":-0.164732,"eighty":-0.074211,"marketCap":3979455},{"date":"2024-08-16","current":-0.091286,"twenty":-0.202441,"median":-0.148887,"eighty":-0.074675,"marketCap":4170088},{"date":"2024-08-23","current":-0.103936,"twenty":-0.201937,"median":-0.114182,"eighty":-0.074801,"marketCap":4747943},{"date":"2024-08-30","current":-0.075134,"twenty":-0.201812,"median":-0.103936,"eighty":-0.074889,"marketCap":3991369},{"date":"2024-09-06","current":-0.071275,"twenty":-0.201372,"median":-0.101719,"eighty":-0.07464,"marketCap":3786324},{"date":"2024-09-13","current":-0.074303,"twenty":-0.199931,"median":-0.100613,"eighty":-0.073472,"marketCap":3947190},{"date":"2024-09-20","current":-0.06477,"twenty":-0.198832,"median":-0.097806,"eighty":-0.072904,"marketCap":3440758},{"date":"2024-09-27","current":-0.047041,"twenty":-0.198734,"median":-0.097089,"eighty":-0.072123,"marketCap":2498940},{"date":"2024-10-04","current":-0.702586,"twenty":-0.201861,"median":-0.097806,"eighty":-0.072322,"marketCap":37323522},{"date":"2024-10-11","current":-0.804153,"twenty":-0.203742,"median":-0.100613,"eighty":-0.072761,"marketCap":42719049},{"date":"2024-10-18","current":-0.880664,"twenty":-0.205452,"median":-0.101719,"eighty":-0.072874,"marketCap":46783580},{"date":"2024-10-25","current":-0.626146,"twenty":-0.208304,"median":-0.106675,"eighty":-0.072904,"marketCap":33262793},{"date":"2024-10-31","current":-0.46218,"twenty":-0.209727,"median":-0.114182,"eighty":-0.073022,"marketCap":24552412},{"date":"2024-11-08","current":-0.379425,"twenty":-0.217422,"median":-0.148887,"eighty":-0.073022,"marketCap":20156203},{"date":"2024-11-15","current":-0.254511,"twenty":-0.219865,"median":-0.164732,"eighty":-0.073315,"marketCap":13520416},{"date":"2024-11-22","current":-0.17644,"twenty":-0.219499,"median":-0.165989,"eighty":-0.073412,"marketCap":9373049},{"date":"2024-11-29","current":-0.107738,"twenty":-0.218815,"median":-0.165889,"eighty":-0.07365,"marketCap":5723366},{"date":"2024-12-06","current":-0.098369,"twenty":-0.217666,"median":-0.160355,"eighty":-0.073901,"marketCap":5225682},{"date":"2024-12-13","current":-0.075065,"twenty":-0.217422,"median":-0.144138,"eighty":-0.074232,"marketCap":3873640},{"date":"2024-12-20","current":-0.057866,"twenty":-0.214393,"median":-0.114182,"eighty":-0.073393,"marketCap":2986104},{"date":"2024-12-27","current":-0.056259,"twenty":-0.21261,"median":-0.110145,"eighty":-0.072963,"marketCap":2903156},{"date":"2025-01-03","current":-0.104658,"twenty":-0.211193,"median":-0.107738,"eighty":-0.072874,"marketCap":5400701},{"date":"2025-01-10","current":-0.087844,"twenty":-0.210021,"median":-0.107738,"eighty":-0.072904,"marketCap":4533072},{"date":"2025-01-17","current":-0.082411,"twenty":-0.209556,"median":-0.104481,"eighty":-0.073022,"marketCap":4252710},{"date":"2025-01-24","current":-0.077155,"twenty":-0.208872,"median":-0.103034,"eighty":-0.073022,"marketCap":3981472},{"date":"2025-01-31","current":-0.090802,"twenty":-0.208442,"median":-0.10198,"eighty":-0.073315,"marketCap":4685695},{"date":"2025-02-07","current":-0.105075,"twenty":-0.208406,"median":-0.10224,"eighty":-0.073412,"marketCap":5422267},{"date":"2025-02-14","current":-0.087185,"twenty":-0.207895,"median":-0.101296,"eighty":-0.07371,"marketCap":4499063},{"date":"2025-02-21","current":-0.067511,"twenty":-0.207113,"median":-0.100929,"eighty":-0.073393,"marketCap":3483788},{"date":"2025-02-28","current":-0.049315,"twenty":-0.206527,"median":-0.100148,"eighty":-0.072875,"marketCap":2544824},{"date":"2025-03-07","current":-0.036777,"twenty":-0.205843,"median":-0.098528,"eighty":-0.072195,"marketCap":1897835},{"date":"2025-03-14","current":-0.020864,"twenty":-0.204719,"median":-0.098369,"eighty":-0.071225,"marketCap":1076656},{"date":"2025-03-21","current":-0.020944,"twenty":-0.204269,"median":-0.097978,"eighty":-0.070572,"marketCap":1080803},{"date":"2025-03-28","current":-0.017312,"twenty":-0.204032,"median":-0.097741,"eighty":-0.069818,"marketCap":893342},{"date":"2025-04-04","current":-0.0122,"twenty":-0.203986,"median":-0.097063,"eighty":-0.069089,"marketCap":629570},{"date":"2025-04-11","current":-0.009323,"twenty":-0.203009,"median":-0.096444,"eighty":-0.068134,"marketCap":481094},{"date":"2025-04-17","current":-0.00958,"twenty":-0.202765,"median":-0.095559,"eighty":-0.067511,"marketCap":494366}],"updateTime":1745274996322}}}